Trade HOOKIPA Pharma Inc. - HOOK CFD

HOOKIPA Pharma Inc. Company profile

About Hookipa Pharma Inc

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company develops immunotherapeutics based on its arenavirus platform that are designed to target and amplify a T cell and immune response to disease. The Company's infectious and oncology product candidates HB-101, HB-201, HB-202 and HB-300. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers. The Company is developing its self-antigen project in this area, HB-300, as a replicating technology-based product candidate in metastatic, hormone-resistant prostate cancer.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Hookipa Pharma Inc revenues increased 1% to $14.6M. Net loss increased 72% to $54.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 60% to $58M (expense), Other income and expenses, net decrease from $1.6M (income) to $1.3M (expense).